PODD— AI Stock Forecast & Price Targets
Published 7/14/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live PODD price forecast →
PODD is a high-quality diabetes device franchise (71% gross margins, 23% ROE, 32% TTM sales growth) trading at ~$162 after a ~43% YTD drawdown, offering a genuine quality-on-sale setup at 20x forward earnings and PEG 0.75. However, the stock sits ~33% below its SMA200, carries unquantified FDA Class I recall liability, and faces a binary Aug 5 earnings print in ~22 days — arguing for accumulation on weakness rather than aggressive buying into the catalyst.
Do NOT chase into the Aug 5 earnings print — it is a binary event in ~22 days with material gap risk both directions given unquantified recall drag. If already accumulating, hold current sizing; if starting fresh, work in 1/3 to 1/2 position now around $155-165 and reserve dry powder for either (a) post-earnings gap-down flush toward $140-150 for a reload, or (b) a confirmed reclaim of $180 with volume post-print. Invalidation for the near-term bounce is a decisive break below $150 with volume; hard stop below $138 (52wk low). Explicit earnings stance: neutral into the print, do not size a swing trade specifically betting on direction — position for either outcome.
1-6 month base case is a base-building recovery toward $185-190 as recall costs get quantified and Omnipod 5 growth reaccelerates, with the SMA200/analyst target cluster at $220-235 as the bull scenario if the Aug 5 print is clean and guidance holds. Expected return range from $162: bear -14% (to ~$140), base +14% (to ~$185), bull +35% (to ~$220). Catalysts: Aug 5 earnings (dominant), Sep 12 William Blair conference, and any FDA recall resolution. What would change my mind: a Q2 guide cut with recall reserves >$100M, or failure of the $138-140 support post-earnings — either would signal deeper de-rating toward $110-125.
1-3 year thesis rests on Omnipod 5 penetration into Type 2 insulin-intensive and pediatric TAM, plus the Omnipod Discover data platform monetization layer. Management targets $4.8B revenue by 2029 (vs $2.9B TTM) — roughly 13% CAGR, achievable given current 32% TTM growth even with deceleration. At 20x forward EPS on a franchise growing EPS ~27% with 71% gross margins, the setup is asymmetric to the upside over 24-36 months IF the current recall/execution issues are transient. Biggest structural risk: GLP-1 agonist penetration reducing insulin-dependent Type 2 patient counts, and competitive escalation from Tandem/Medtronic/integrated CGM+pump platforms compressing pricing and share.
The underlying business quality is genuinely elite: Q1'26 revenue of $761.7M with 69.5% gross margin and 16% operating margin, TTM sales up 31.9%, ROE of 23%, and ROIC of 13.6%. Revenue has scaled from $649M (Q2'25) to $784M (Q4'25) to $762M (Q1'26), demonstrating durable double-digit sequential growth. Balance sheet is healthy — $480M cash, current ratio 2.49, debt/equity 0.73, and $619M TTM operating cash flow supporting the capacity build. The one blemish is FCF quality: Q4'25 capex spiked to $149M (vs $23-31M in adjacent quarters), compressing FCF to $34M that period; Q1'26 normalized back to $86M FCF. Forward P/E of 20.1x on projected 26.7% EPS growth (PEG 0.75) is reasonable for this margin/growth profile — the multiple compression from earlier this year has largely restored valuation sanity. Capital allocation is R&D/capacity-focused with no dividend, appropriate for the growth stage. The unquantified FDA Class I recall liability is the primary open question on the P&L.
Multi-timeframe picture is a broken uptrend attempting to base. On the weekly, PODD has round-tripped from $354 (52wk high) to $138 (52wk low), currently at $162 — a genuine bear market drawdown. Daily chart shows a slow grind higher off May lows, with price now +5.5% above SMA20 and +5.4% above SMA50 but still -33% below SMA200 (~$243) — the primary structural resistance. RSI at 56 is neutral-constructive, not extended. The 1h chart shows near-term consolidation around $160-162 after a rally from ~$140. The model's forecast band is contradictory across timeframes: 1h forecasts a drop to ~$151, while 1d and 1wk project a sharp rally to $243-263 — and the 1wk forecast has historically been beaten by a naive baseline (50% vs 80%), so I discount the aggressive upside projections. Key levels: support $150 → $138-140 (52wk low, must hold); resistance $175 → $185-190 (recent pivot) → $220-243 (SMA200 + analyst cluster).
Signal: the Calm partnership (Jul 14) is a modest brand/engagement enhancer with limited financial impact, but reinforces the Omnipod ecosystem narrative. Stifel cut its price target to $225 (from $250) on Jul 10 while maintaining buy — sell-side is trimming but not capitulating, with mean target still $233.65 and Recom 1.43 (strong buy skew). Board refresh and Russell 2500 inclusion (Jul 1) bring passive fund inflows. Insider buying by President McEvoy (~$1M in shares) is a positive confidence signal. Noise/overhangs: the class action shareholder lawsuit deadline (Aug 31) and unquantified FDA Class I recall remain the key regulatory tail risks. The recent 8-K (Jun 25) noted an executive change and Reg FD guidance disclosure — worth monitoring but not thesis-breaking. Congressional trades show two spousal SELL transactions (~$100-250K each) in late April/early May, a mild negative positioning signal but pre-dating current levels.
- Omnipod 5 platform expansion including Jun 5 2026 over-the-air algorithm upgrade and expanded compatibility with Abbott FreeStyle Libre 3 Plus
- Type 2 insulin-intensive and pediatric label expansions materially widening TAM beyond core Type 1 base
- International rollout including Spain launch with bundled Discover data platform extending EU footprint
- Omnipod Discover data platform opening recurring/software monetization layer beyond hardware sales
- Management's $4.8B revenue target by 2029 vs $2.9B TTM implies durable double-digit growth runway
- Calm partnership (Jul 14) and ecosystem plays enhancing patient stickiness and brand differentiation
- Unquantified FDA Class I recall liability — warranty accrual, remediation costs, and litigation reserves not yet reflected in reported numbers
- Aug 5 earnings is a binary event with gap risk in either direction; first real read on recall drag and forward guide
- Broken weekly chart with price ~33% below SMA200 (~$243) — no confirmed trend reversal yet, base-building at best
- Sell-side revision trend still negative (Stifel cut target to $225 on Jul 10) despite maintained buy ratings
- Class action shareholder lawsuit deadline Aug 31 creates additional legal overhang and headline risk
- GLP-1 agonist secular headwind potentially reducing insulin-dependent Type 2 patient population over 3-5 years
- Competitive pressure from Tandem, Medtronic, and integrated CGM+pump platforms (Abbott/DXCM) risks share/pricing
- Q4'25 capex step-up to $149M vs ~$25-30M run-rate pressures near-term FCF conversion until capacity is absorbed
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord